BSE - 30 PE

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Rubicon Research has informed that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection (triggered by a product filing) of the company’s manufacturing facility located at Plot No. K30/4 & 30/5, Additional M.I.D.C., Anand Nagar, Ambernath, Maharashtra, India from Wednesday, 21 October 2026 to Thursday, 29 October 2026. This was a comprehensive GMP inspection in addition to the product application under review. Upon conclusion, a Form 483 containing 3 observations with respect to system improvement and 2 observations with respect to product application under review were issued, all 5 of which are procedural in nature and do not relate to data integrity. The company is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner. All its manufacturing as well as R&D facilities have now been inspected by the US FDA in the recent past and it has enclosed the status of all its operational facilities.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fabtech Technologies has informed that it enclosed the Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026.

The above information is a part of company’s filings submitted to BSE.

With reference to the clarification dated October 27, 2026, regarding the significant movement in the price of the securities of the Company, NMS Global has submitted: The Company is not aware of any undisclosed material event, information, or development that would require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which could have a bearing on the movement in the price of its securities. The Company has been making disclosures to the Stock Exchanges from time to time in accordance with the applicable provisions of the SEBI (LODR) Regulations, 2015. The Company remains committed to ensuring timely disclosure of all material information and maintaining transparency with its shareholders and the investing public. The movement in the price of the Company's securities appears to be market-driven, and the Company is not in a position to comment on the specific reasons for such movement. The company has confirmed that, should any material event or information requiring disclosure arise, the Company shall make the requisite disclosure to the Stock Exchanges in accordance with applicable regulatory requirements.

The above information is a part of company’s filings submitted to BSE.

According to the data released by the NSE, the Foreign Institutional Investors (FIIs) were net buyers of Rs 6949.86 crore in index futures and options segments, as per Thursday’s data, October 29, 2026.

FIIs were net sellers of index futures to the tune of Rs 423.42 crore and net buyers of index options worth Rs 7373.28 crore. In the stock segment, FII’s were net buyers of stock futures worth Rs 2111.56 crore and they bought stock options worth Rs 81.26 crore.